Outcome Any outcome Wins (met endpoint / approved) Flops (missed / terminated / rejected) Met endpoint Missed endpoint Terminated / discontinued Mixed results Trial update Approved Rejected (CRL)
Phase Any phase Phase 1 Phase 1/2 (1) Phase 2 (8) Phase 2/3 Phase 3 (11) Phase 4
Condition Any condition Advanced Solid Tumor (1) Alcohol Use Disorder (AUD) (1) Autism Spectrum Disorder (1) Bipolar 1 Disorder (1) Chronic Spontaneous Urticaria (1) Generalized Anxiety Disorder (2) Metastatic Non-Small Cell Lung Cancer (1) Pneumococcal Disease (1) Post Bariatric Hypoglycemia (1) Pulmonary Hypertension (2) Recurrent IDH1-Mutant High-Grade Glioma (1) Relapsed Diffuse Large B-Cell Lymphoma (1) Schizophrenia (1) SLE (1) Wet Age-related Macular Degeneration (1) Wilson Disease (1)
Company Any company ADC Therapeutics (1) Altimmune (1) Alumis (1) Amylyx Pharmaceuticals (1) ArriVent (1) Celldex (1) Definium Therapeutics (2) Kodiak Sciences (1) MapLight (1) MapLight Therapeutics (1) Monopar (1) NeOnc Technologies (1) Rapport Therapeutics (1) Roivant (1) Silence Therapeutics (1) Tenax Therapeutics (1) TG Therapeutics (1) TransCode Therapeutics Successfully (1) Vaxcyte (1)
Company type All companies Public companies only
Patients Any size Under 100 patients 100–499 patients 500+ patients
Stock move (24h) Any move Big movers (±10%+) Up 10% or more Down 10% or more Any rise Any fall 24h price pending Private / not listed
Announced Any time Today Last 7 days Last 30 days
